$SLS The crazy thing is that SLS009 *on its own* at $12.50 is still one of the better buys in biotech right now. Comparable drugs have been snatched up earlier in development for $2B, $3B, even $5B+. SLS009 has already proven its safety profile and effectiveness, and is now just waiting for P2 data to come in and back that data up (in an even healthier population) during Q4 before it’s up for accelerated approval via the FDA. It appears the market has been so busy litigating the success of GPS/REGAL that it missed SLS009 altogether. When you see people linking some other random bio stock they are trying to pump, keep in mind that you, right now, have a play that’s at least as good and it’s already a part of your portfolio, quietly waiting until later this year.
在 X 查看 ↗